COMMUNIQUÉS West-GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences
04/09/2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that [...]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
04/09/2025
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current [...]
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
04/09/2025
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and [...]
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
04/09/2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for [...]
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
04/09/2025
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, and Catalent ® , a global leader in enabling pharma, biotech, and consumer health partners to [...]
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
04/09/2025
Topline data anticipated in early Q4 2025 BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company [...]
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
04/09/2025
Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for [...]
Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases
04/09/2025
Engages Former FDA Director of Division of Cardiology and Nephrology, Norman Stockbridge, M.D., Ph.D., to Advise on Walden’s Clinical Pipeline in Rare Kidney Diseases Utilizes Rare Kidney Disease Patient Advocacy Group [...]
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
04/09/2025
NDA remains on track for FDA PDUFA goal date of January 31, 2026 Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. ( [...]
Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports
04/09/2025
Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as Vice President and Head, CMC Strategy and Manufacturing Hinge Bio publishes [...]
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
04/09/2025
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
04/09/2025
WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the [...]
Algernon Pharmaceuticals Announces Name Change to Algernon Health
04/09/2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is [...]
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
04/09/2025
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
04/09/2025
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared [...]
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
04/09/2025
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical [...]
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
04/09/2025
CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on [...]
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
04/09/2025
The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 [...]
Immunocore to present at upcoming investor conferences
04/09/2025
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company [...]

Pages